Sensitivity Of Golgi Protein 73 Research Articles

Study of Golgi protein 73 in patients with hepatitis C virus-related hepatocellular carcinoma

ObjectiveThe aim of the present work is to investigate the expression of Golgi protein 73 (GP73) in serum in patients with hepatocellular carcinoma (HCC) and determine its efficacy as a screening test in early detection of HCC.BackgroundSerum GP73 is a promising biomarker for detection of HCC.Patients and methodsThis case–control study involved 30 patients with HCC, 30 patients with liver cirrhosis, and 15 healthy controls. Clinical examination, abdominal ultrasonography, and triphasic computed tomography for focal lesion were performed. Liver function tests were performed using clinical autoanalyzer, serum α-fetoprotein (AFP) was measured using enzyme-linked immune-sorbent assay method, and GP73 was determined by enzyme-linked immune-sorbent assay kit for GP73. Data were collected and statistically analyzed.ResultsGP73 was highly significantly higher in HCC group than cirrhotic and control groups. The sensitivity of GP73 in diagnosis of HCC was 83% and the specificity was 74%, at a cutoff point of 111 ng/ml, elicited from the receiver operator characteristic curve, with very good area under curve of 0.909, whereas that the sensitivity of AFP was 36.7% and the specificity was 100% at a cutoff point of 400 ng/ml, elicited from the receiver operator characteristic curve, with very good area under curve of 0.903.ConclusionGP73 is highly associated with HCC and is more sensitive than AFP for early detection of HCC.

Expression profiles and differential diagnostic value of serum Golgi protein-73 in patients with liver cirrhosis and primary hepatic carcinoma

To investigate the expression profiles of serum Golgi protein-73 (GP73) in liver cirrhosis and primary hepatic carcinoma (PHC) and determine its clinical value for differential diagnosis. Serum protein expressions of GP73 and alpha-fetoprotein (AFP) were detected by enzyme-linked immunosorbent assay and chemiluminescence assay, respectively, in patients with PHC (n=80), liver cirrhosis (n=65), and healthy controls (n=50). Inter-group changes were assessed by Kruskal-Wallis test, and significance of these differences was assessed by Mann-Whitney test. A receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic efficiency and determine the cut-off values for GP73 and AFP. Sensitivity and specificity were compared by the Chi-squared test. Correlation between serum GP73 expression and clinical parameters was determined by Spearman's rank correlation analysis. The PHC group showed significantly higher serum GP73 (282.0 mug/L) than the liver cirrhosis group (211.8 mug/L) and control group (58.3 mug/L) (H = 93.30, P less than 0.01). For differential diagnosis of PHC and liver cirrhosis, the cut-off value was 318.1 mug/L for GP73 and 13.4 mug/L for AFP. Sensitivity of GP73 was lower than AFP (45% (36/80) vs. 65% (52/80); X2 = 8.02, P less than 0.05). Specificity of GP73 was lower than AFP but no significance was found (83.1% (54/65) vs. 87.7% (57/65); X2=0.27, P more than 0.05). The areas under the ROC curves were not significantly different between GP73 and AFP (0.65 (95% confidence interval (CI): 0.54~0.72) vs. 0.75 (95% CI: 0.67~0.83); Z = 1.88, P more than 0.05). The area under the ROC curves increased but not significantly (0.80 (95% CI: 0.73~0.88) vs. 0.75 (95% CI: 0.67~0.83); Z=2.61, P more than 0.05). Serum GP73 was correlated with liver cirrhosis (r=0.27), vascular invasion (r=0.29), and TNM staging (r=0.27) (all P less than 0.05), but not with sex (r=0.13), age (r=0.10), enhanced AFP (> 13.4 mug/L; r=0.03), tumor size (r=0.18), or distant metastasis (r=0.04), all P less than 0.05. Serum GP73 and AFP have comparable diagnostic efficiency, but the sensitivity of AFP is superior for differential diagnosis of liver cirrhosis and primary hepatic carcinoma. Elevated serum GP73 may be correlated with liver tumor load and aggressiveness.